Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Butt

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Alimentary Pharmacology & Therapeutics|November 29, 2017
Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVESA A Butt, P Yan, O S Shaikh, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2006
Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjectsA A Butt, A C Justice, M Skanderson, et al.
Alimentary Pharmacology & Therapeutics|November 5, 2016
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVESA A Butt, Y Ren, K Marks, et al.
Alimentary Pharmacology & Therapeutics|July 27, 2016
Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVESA A Butt, P Yan, K Marks, et al.
Alimentary Pharmacology & Therapeutics|May 4, 2011
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirinA A Butt, T Umbleja, J W Andersen, et al.
Journal of Viral Hepatitis|December 12, 2007
Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veteransA A Butt, U A Khan, K A McGinnis, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2017
Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVESD K Li, P Yan, A-B Abou-Samra, et al.
Journal of Viral Hepatitis|February 26, 2018
Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from ERCHIVESJ Y Chen, Y Ren, P Yan, et al.
Journal of Viral Hepatitis|October 10, 2012
Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 studyN Kemmer, L Hua, J W Andersen, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2018
Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES studyA A Butt, Y Ren, A Puenpatom, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Alimentary Pharmacology & Therapeutics|November 29, 2017
Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVESA A Butt, P Yan, O S Shaikh, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2006
Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjectsA A Butt, A C Justice, M Skanderson, et al.
Alimentary Pharmacology & Therapeutics|November 5, 2016
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVESA A Butt, Y Ren, K Marks, et al.
Alimentary Pharmacology & Therapeutics|July 27, 2016
Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVESA A Butt, P Yan, K Marks, et al.
Alimentary Pharmacology & Therapeutics|May 4, 2011
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirinA A Butt, T Umbleja, J W Andersen, et al.
Journal of Viral Hepatitis|December 12, 2007
Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veteransA A Butt, U A Khan, K A McGinnis, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2017
Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVESD K Li, P Yan, A-B Abou-Samra, et al.
Journal of Viral Hepatitis|February 26, 2018
Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from ERCHIVESJ Y Chen, Y Ren, P Yan, et al.
Journal of Viral Hepatitis|October 10, 2012
Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 studyN Kemmer, L Hua, J W Andersen, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2018
Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES studyA A Butt, Y Ren, A Puenpatom, et al.
Pageof 3